Should I buy Hikma Pharmaceuticals stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Hikma Pharmaceuticals for over three years. Every month, over a million users in the UK trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Hikma Pharmaceuticals.

What is Hikma Pharmaceuticals?

What is the Hikma Pharmaceuticals stock price?

The price of Hikma Pharmaceuticals stock is declining this week. The current share price stands at 1,981 GBp, reflecting a 0.55% drop in the last 24 hours and a 7.77% decrease over the past week. The company has a market capitalisation of £4.44 billion, with a three-month average daily volume of 509,170 shares. The stock offers a P/E ratio of 16.93, a dividend yield of 3.09%, and a beta of 0.66. While recent volatility is notable, the solid dividend and attractive valuation position Hikma Pharmaceuticals as a stock with potential for long-term investors.

Our Full Analysis of Hikma Pharmaceuticals Stock

Having thoroughly reviewed Hikma Pharmaceuticals’ latest financial results and observed the stock’s development over the past three years, we have synthesised a wide array of data sources—including financial indicators, technical signals, peer comparisons, and larger market trends—through our proprietary analytical models. This allows us to pinpoint both the performance drivers and emerging opportunities that matter most to UK investors. So, why might Hikma Pharmaceuticals stock once again become a strategic entry point into the global healthcare and pharmaceutical sector in 2025?

Recent performance and market context

Hikma Pharmaceuticals has displayed solid resilience in a dynamic market. Trading at 1,981 GBp as of July 2025, the stock recorded a 7.37% annual appreciation despite a recent 7.77% weekly pullback. Over the last year, the company’s market capitalisation reached £4.44 billion, reflecting confidence in its hybrid model spanning generics, branded products, and specialty injectables. Notably, a surge in revenue (+8.8% in 2024) exceeded market expectations and was underpinned by strong performance in both the US and MENA regions.

Several positive events have supported this positive trend. In June 2025, Hikma announced a $1 billion investment in expanding its US manufacturing and R&D by 2030—one of the largest expansions in its history. Recent FDA approvals, including the launch of TYZAVAN™ and STARJEMZA®, further solidified its position as a leader in hospital injectables and biosimilars. With the global generics and biosimilars segment robust and regulatory frameworks in the US and UK supportive, the macroeconomic landscape remains a tailwind for Hikma’s core business.

Technical analysis

From a technical standpoint, Hikma Pharmaceuticals’ price action suggests the potential for a new positive cycle. The 14-day RSI sits at 43.23—neutral but with scope for upside as momentum recovers. While shorter-term moving averages (20, 50, and 100 days) have issued a short-term sell signal, the 200-day moving average at 1,991.31 GBp confirms long-term upward structure. The MACD, at -8.21, is currently indicating a buy opportunity, especially as price approaches key support in the 1,930–1,958 GBp zone.

Importantly, the stock maintains critical support levels and is now trading just below its medium-term resistance band (2,026–2,054 GBp), suggesting a technical inflection point. The healthy 6-month and 1-year trends, together with robust volume, highlight the market’s willingness to re-rate the stock as new catalysts emerge. For short- and medium-term strategies, this could represent an attractive entry phase ahead of a potential rebound.

Fundamental analysis

Hikma Pharmaceuticals’ fundamentals justify renewed investor interest. Revenues grew sharply to $3.13 billion in 2024, an 8.8% rise fuelled by double-digit expansion in its generics and injectables divisions. Net profit reached $359 million, consistently outpacing sector norms and supporting robust dividend payments, with a current yield of 3.09%—notable in the defensive pharmaceutical sector. The price/earnings ratio stands at a compelling 16.93, indicating an attractive value relative to projected profit growth.

Beyond traditional metrics, Hikma’s structural strengths are clear:

• Leadership in hospital injectables
• Diversified operating base in 10 countries
• Strong R&D capabilities and a growing FDA approval pipeline
• Strategic focus on the high-growth US and MENA regions

This foundation has enabled Hikma to consistently outperform global peers, successfully navigating pressures in pricing and competition. The company’s balance sheet remains strong, with improved leverage, continuous investment in innovation, and a decentralised operating model fostering agility.

Volume and liquidity

Share liquidity is a standout feature of Hikma Pharmaceuticals, with a sustained average daily volume of over 509,000 shares, ensuring low transaction costs and fluidity for both retail and institutional investors. The 57% institutional ownership ratio underscores market confidence and facilitates dynamic price discovery. The sizeable free float and regular turnover support ongoing valuation re-ratings as new information becomes available. Stability and recurring capital flows indicate that the market views Hikma as a long-term value creator rather than a speculative play.

Catalysts and positive outlook

The outlook for Hikma Pharmaceuticals remains highly constructive, underpinned by several bullish catalysts:

• Major $1 billion investment plan in the US to boost manufacturing and R&D capacity, enhancing its competitive advantage in injectables and biosimilars.
• Recent and anticipated FDA approvals, expanding its commercial footprint and supporting further revenue growth.
• Ongoing momentum in generics and branded drugs as healthcare demand rises and pricing stabilises.
• Strong pipeline of innovative products, with several new launches scheduled for 2025.
• Geographical and segment diversification, reducing risk and increasing revenue predictability.

Further, the positive market sentiment is fuelled by sector-wide trends: global demand for affordable medicines, regulatory initiatives favouring generics, and continued healthcare spending. Hikma’s focused ESG initiatives, including reduced environmental impact and increased social responsibility, also add to its long-term attractiveness for a broad investor base.

Investment strategies

Investors have several favourable scenarios for strategic entry into Hikma Pharmaceuticals. For short-term trades, the current technical support near 1,950 GBp offers a potential rebound zone, especially as momentum stabilises and new positive news is anticipated. Medium-term investors may target accumulation during consolidation phases, as the company’s pipeline and expansion efforts move towards commercial launch. For long-term allocators, the combination of above-market dividend yield, earnings growth, robust defensive sector exposure, and transformational investment in high-value geographies justifies patient, staged buy-ins.

Hikma’s resilient track record and continued expansion signal a stock well-suited to a range of objectives:

• Short-term: Tactical trades around FDA approvals or earnings
• Medium-term: Hold for pipeline news and expansion execution
• Long-term: Buy-and-hold for compounding returns and sector outperformance

With a current market consensus price target of 2,575 GBp—over 30% above current levels—upside potential appears credible on multiple horizons.

Is it the right time to buy Hikma Pharmaceuticals?

In sum, Hikma Pharmaceuticals brings to the table a blend of robust revenue growth, disciplined capital allocation, innovative leadership, and sector-leading positions—now coupled with major planned investments to drive its next phase. The current share price and valuation appear to adequately discount short-term headwinds and create an attractive setup for investors with an eye on forward growth. The fundamentals, technical picture, and pipeline of catalysts all suggest that renewed interest is justified and that the stock may be entering a new bullish phase.

Hikma Pharmaceuticals embodies the type of resilient, innovative, and globally relevant healthcare leader that delivers long-term value—and current conditions seem to represent an excellent opportunity for those looking to benefit from the next wave of sector growth and transformation.

How to buy Hikma Pharmaceuticals stock in the UK?

Buying Hikma Pharmaceuticals stock online is straightforward and secure when you use a trusted, UK-regulated brokerage platform. Investors can choose between two main options: direct cash (spot) purchase, where you own real shares, or trading contracts for difference (CFDs), which let you speculate on price movements without owning the stock. Each method has its benefits, letting you suit your own investment style and risk appetite. For a detailed comparison of brokers offering both options and their fees, see the table further down the page.

Spot buying

A cash purchase means you buy and own real Hikma Pharmaceuticals shares in your name. Standard fees usually include a fixed commission per order, typically around £5 to £10 on UK platforms.

Gain scenario

For example, if the Hikma Pharmaceuticals share price is 1,981p (about £19.81), you can buy around 50 shares with a £1,000 stake, including a brokerage fee of about £5.

If the share price rises by 10%, your shares would be worth £1,100.

Result: +£100 gross gain, or +10% return on your investment.

Trading via CFD

CFD trading allows you to speculate on Hikma Pharmaceuticals share price movement without owning the physical shares. The main costs here are the spread (the difference between bid and ask prices) and potential overnight financing charges if you keep the position open over several days.

Gain scenario

For example, you open a CFD on Hikma Pharmaceuticals with a £1,000 deposit and 5x leverage.

This gives you £5,000 market exposure.

If the stock rises by 8%, your position earns 8% × 5 = 40%.

Result: +£400 gain on your £1,000 deposit (excl. fees).

Final advice

Before investing, always compare the fees, minimum requirements, and conditions set by different brokers—these can impact your overall returns. The best method depends on your risk profile and whether you want to take ownership of shares or trade shorter-term movements. For personalised pricing and options, the broker comparator further down the page will help you find what’s right for you.

Our 7 tips for buying Hikma Pharmaceuticals stock

The latest news about Hikma Pharmaceuticals

Hikma Pharmaceuticals announced a strategic £1 billion US expansion, reinforcing its UK operations’ global role. The June 2025 commitment positions its London headquarters and R&D management at the centre of growing US-UK synergies, enhancing visibility of British pharmaceutical expertise.

The company’s London-listed shares maintain solid liquidity and market cap, signalling persistent investor confidence. With a current market cap of £4.44 billion and average daily trading volume of 509,170 shares, Hikma Pharmaceuticals remains a mainstay among FTSE healthcare stocks, attracting sustained institutional interest from UK-based funds.

Recent outperforming earnings confirm strong UK corporate governance and strategic execution. 2024 financial results with 8.8% revenue growth and margin improvement exceeded analyst expectations, bolstering management credibility and underlining robust stewardship from its London-based executive team.

Ongoing product innovation led by UK talent has secured key FDA approvals, supporting future UK export growth. Recent US FDA authorisations for TYZAVAN™ and STARJEMZA® reflect R&D capabilities rooted in the UK, with anticipated positive impacts for both domestic production and international demand for British-developed generics and biosimilars.

Dividend yields and risk indicators attract UK-focused income and defensive investors. A current 3.09% dividend yield and low beta (0.66) make Hikma Pharmaceuticals a preferred option for British investors seeking stable income and lower volatility within FTSE portfolios.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.